JP2013534804A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534804A5
JP2013534804A5 JP2013505074A JP2013505074A JP2013534804A5 JP 2013534804 A5 JP2013534804 A5 JP 2013534804A5 JP 2013505074 A JP2013505074 A JP 2013505074A JP 2013505074 A JP2013505074 A JP 2013505074A JP 2013534804 A5 JP2013534804 A5 JP 2013534804A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
residue
alk
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013505074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534804A (ja
JP6223822B2 (ja
Filing date
Publication date
Priority claimed from US12/761,050 external-priority patent/US8383793B2/en
Application filed filed Critical
Publication of JP2013534804A publication Critical patent/JP2013534804A/ja
Publication of JP2013534804A5 publication Critical patent/JP2013534804A5/ja
Application granted granted Critical
Publication of JP6223822B2 publication Critical patent/JP6223822B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013505074A 2010-04-15 2011-04-13 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物 Expired - Fee Related JP6223822B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/761,050 US8383793B2 (en) 2010-04-15 2010-04-15 Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
US12/761,050 2010-04-15
PCT/US2011/032204 WO2011130340A1 (en) 2010-04-15 2011-04-13 Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (alk) kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016195911A Division JP2017018141A (ja) 2010-04-15 2016-10-03 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2013534804A JP2013534804A (ja) 2013-09-09
JP2013534804A5 true JP2013534804A5 (enExample) 2014-05-29
JP6223822B2 JP6223822B2 (ja) 2017-11-01

Family

ID=44314994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013505074A Expired - Fee Related JP6223822B2 (ja) 2010-04-15 2011-04-13 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物
JP2016195911A Pending JP2017018141A (ja) 2010-04-15 2016-10-03 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016195911A Pending JP2017018141A (ja) 2010-04-15 2016-10-03 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物

Country Status (10)

Country Link
US (2) US8383793B2 (enExample)
EP (1) EP2558490B1 (enExample)
JP (2) JP6223822B2 (enExample)
KR (1) KR20130064067A (enExample)
CN (1) CN103201286B (enExample)
AU (1) AU2011240636B2 (enExample)
BR (1) BR112012026239A2 (enExample)
CA (1) CA2796306A1 (enExample)
RU (1) RU2012148450A (enExample)
WO (1) WO2011130340A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN102498377B (zh) 2009-08-13 2014-05-14 奇姆德恩医疗有限公司 压力指示器
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
CN103429291A (zh) 2011-02-02 2013-12-04 梅田有限公司 改进的人工气道
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
JP6205216B2 (ja) 2012-09-24 2017-09-27 アークレイ株式会社 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2015157624A2 (en) * 2014-04-10 2015-10-15 Memorial Sloan-Kettering Cancer Center A novel isoform of anaplastic lymphoma kinase and its uses
US9428812B2 (en) * 2014-04-28 2016-08-30 Insight Genetics, Inc. Kit comprising primers for amplifying ALK kinase domain nucleic acids
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
WO2016115480A1 (en) * 2015-01-16 2016-07-21 Vedantra Pharmaceuticals, Inc. Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
US20180177792A1 (en) * 2015-05-29 2018-06-28 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
UA125025C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
MX392604B (es) 2016-05-18 2025-03-24 Array Biopharma Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
CN107885972B (zh) * 2016-09-30 2021-07-27 广州华大基因医学检验所有限公司 一种基于单端测序的融合基因检测方法及其应用
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110716042A (zh) * 2019-10-23 2020-01-21 郑州大学 一种用于卵巢癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法
CN111235272B (zh) * 2020-01-10 2023-07-07 厦门艾德生物医药科技股份有限公司 一次性检测肺癌多重基因突变的组合物及其应用
EP4139440B1 (en) 2020-04-22 2026-08-19 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CN112391390A (zh) * 2020-11-19 2021-02-23 山西大学 飞蝗网格蛋白重链基因及其靶向dsRNA的合成与应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
ATE88761T1 (de) 1986-01-10 1993-05-15 Amoco Corp Kompetitiver homogener test.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
DE69034263D1 (de) 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1992000968A1 (en) 1990-07-10 1992-01-23 Smithkline Beecham Corporation Oxamides
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
KR100236506B1 (ko) 1990-11-29 2000-01-15 퍼킨-엘머시터스인스트루먼츠 폴리머라제 연쇄 반응 수행 장치
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
AU645915B2 (en) 1991-07-23 1994-01-27 F. Hoffmann-La Roche Ag Improvements in the in situ PCR
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JP3537141B2 (ja) 1992-10-30 2004-06-14 ザ ゼネラル ホスピタル コーポレーション 新種蛋白質分離のための相互作用を用いる補捉システム
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
AU713667B2 (en) 1996-04-12 1999-12-09 Phri Properties, Inc. Detection probes, kits and assays
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
EP1092047B1 (en) 1998-07-02 2009-08-26 Gen-Probe Incorporated Molecular torches
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
DE60014762T2 (de) 1999-05-24 2005-10-13 Tosoh Corp., Shinnanyo Methode zum Nachweis von Ribonukleinsäuren
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2004235747B2 (en) 2003-05-01 2009-05-28 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP2042191B1 (en) * 2007-09-28 2013-01-02 Roberto Chiarle Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
TWI518325B (zh) * 2010-02-04 2016-01-21 自治醫科大學 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療

Similar Documents

Publication Publication Date Title
RU2012148450A (ru) Способы и композиции для диагностики и лечения рака, резистентного к ингибиторам киназы анапластической лимфомы (alk)
US10143187B2 (en) Transferrin receptor transgenic models
Yoo et al. Somatic mutations of the KEAP1 gene in common solid cancers
US20230279496A1 (en) Clear Cell Renal Cell Carcinoma Biomarkers
CN107002289B (zh) 用于定量评价dna-蛋白质复合物密度的组合物和方法
JP2015531590A5 (enExample)
JP2020536560A5 (enExample)
CA3150454A1 (en) Novel crispr dna targeting enzymes and systems
DK2715365T3 (en) ROSE KINASE IN LUNG CANCER
FI3774897T3 (fi) Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon
JP2010259438A5 (enExample)
CA2413475A1 (en) Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
RU2009135270A (ru) Способы выявления воспалительного заболевания кишечника
JP2014503180A5 (enExample)
JP2013518579A5 (enExample)
US20180066322A1 (en) Biomarkers associated with cdk inhibitors
JP2008512984A5 (enExample)
Kueng et al. Regulating repression: roles for the sir4 N-terminus in linker DNA protection and stabilization of epigenetic states
JP2010528584A5 (enExample)
Mazzola et al. Inhibition of Yap2 activity by MAPKAP kinase Rck1 affects yeast tolerance to cadmium
JP2010131022A5 (enExample)
JP2013503644A5 (enExample)
EP2628011B1 (en) Ilk gene as marker for erlotinib treatment
CN1936584A (zh) 作为毒性效应标志的脂肪酸结合蛋白4
US10590168B2 (en) Substrates for FLT3 kinase and uses thereof